國立虎尾科技大學 |

Major Depressive Disorder = Rethinking and Understanding Recent Discoveries /

紀錄類型:	書目-語言資料,印刷品 : Monograph/item
正題名/作者:	Major Depressive Disorder/ edited by Yong-Ku Kim.
其他題名:	Rethinking and Understanding Recent Discoveries /
其他作者:	Kim, Yong-Ku.
面頁冊數:	XI, 563 p. 30 illus., 22 illus. in color.online resource. :
Contained By:	Springer Nature eBook
標題:	Psychopharmacology. -
電子資源:	https://doi.org/10.1007/978-981-33-6044-0
ISBN:	9789813360440

Major Depressive Disorder = Rethinking and Understanding Recent Discoveries /
Major Depressive DisorderRethinking and Understanding Recent Discoveries /[electronic resource] :edited by Yong-Ku Kim. - 1st ed. 2021. - XI, 563 p. 30 illus., 22 illus. in color.online resource. - Advances in Experimental Medicine and Biology,13052214-8019 ;. - Advances in Experimental Medicine and Biology,889.

Section I. Re-thinking depression from a network perspective -- Chapter 1. Phenotype network and brain structural covariance network of major depression -- Chapter 2. Task MRI-based functional brain network of major depression -- Chapter 3. White matter-based structural brain network of major depression -- Chapter 4. The application of a machine learning-based brain MRI approach in major depression -- Chapter 5. Resting state functional MRI in major depression -- Chapter 6. Development of neuroimaging–based biomarkers in depressive disorder -- Section II. Current diagnostic and neurobiological issues -- Chapter 7. Challenges and strategies for current classifications of depressive disorders: proposal for future diagnostic standards -- Chapter 8. Epigenetics: a missing link between early life stress and depression -- Chapter 9. Glia- neuron communications and gut-brain axis in depression -- Chapter 10. Apoptosis and proliferation markers in major depression -- Chapter 11. A load to find clinically useful biomarkers for depression -- Chapter 12. Pharmacogenomic tests for diagnosis and treatment prediction in depression -- Section III. Current specific treatments for depression -- Chapter 13. Biofeedback and neurofeedback for depression: a critical review -- Chapter 14. Cognitive behavioral therapy and mindfulness based cognitive therapy for depressive disorders -- Chapter 15. Acceptance Commitment Therapy (ACT) for major depressive disorder -- Chapter 16. Neurostimulation therapies in depressive disorders -- Chapter 17. Ketamine in major depression : New rapid antidepressant -- Chapter 18. Psychodynamic therapy in depressive disorders -- Chapter 19. Well-being therapy in depressive disorders -- Chapter 20. Complementary and alternative medicine in the treatments of depressive disorders -- Chapter 21. Current psychopharmacology algorithm for major depressive disorder -- Section IV. Promising future treatments for depression -- Chapter 22. Novel psychopharmacology for depressive disorders -- Chapter 23. Cannabinoid agents for depressive disorders -- Chapter 24. Virtual Reality for the treatment of depressive disorders -- Chapter 25. Epigenetic Therapy in depressive disorders -- Chapter 26. Induced pluripotent stem (iPS) cells technology: potential therapeutic targets for depression -- Chapter 27. Vaccination and immunotherapy for major depression -- Chapter 28. Psychedelic Medicines in major depression: progress and future challenges -- Chapter 29. Precision Psychiatry: Biomarker guided Tailored Therapy for Effective Treatment and Prevention in major depression. .

This book reviews all aspects of major depressive disorder (MDD), casting light on its neurobiological underpinnings and describing the most recent advances in management. The book is divided into four sections, the first of which discusses MDD from a network science perspective, highlighting the alterations in functional and structural connectivity and presenting insights achieved through resting state functional MRI and the development of neuroimaging-based biomarkers. The second section examines important diagnostic and neurobiological issues, while the third considers the currently available specific treatments for MDD, including biofeedback, neurofeedback, cognitive behavioral therapy, acceptance and commitment therapy, neuromodulation therapy, psychodynamic therapy, and complementary and alternative medicine. A concluding section is devoted to promising emerging treatments, from novel psychopharmacological therapies through to virtual reality treatment, immunotherapy, biomarker-guided tailored therapy, and more. Written by leading experts from across the world, the book will be an excellent source of information for both researchers and practitioners.

ISBN: 9789813360440

Standard No.: 10.1007/978-981-33-6044-0doiSubjects--Topical Terms:

644799
Psychopharmacology.

LC Class. No.: RC321-580

Dewey Class. No.: 612.8

Major Depressive Disorder = Rethinking and Understanding Recent Discoveries /
LDR:05247nam a22004095i 4500 001 1050481
003 DE-He213
005 20210818171040.0
007 cr nn 008mamaa
008 220103s2021 si | s |||| 0|eng d
020 $a 9789813360440 $9 978-981-33-6044-0
024 7 $a 10.1007/978-981-33-6044-0 $2 doi
035 $a 978-981-33-6044-0
050 4 $a RC321-580
072 7 $a PSAN $2 bicssc
072 7 $a MED057000 $2 bisacsh
072 7 $a PSAN $2 thema
082 0 4 $a 612.8 $2 23
245 1 0 $a Major Depressive Disorder $h [electronic resource] : $b Rethinking and Understanding Recent Discoveries / $c edited by Yong-Ku Kim.
250 $a 1st ed. 2021.
264 1 $a Singapore : $b Springer Singapore : $b Imprint: Springer, $c 2021.
300 $a XI, 563 p. 30 illus., 22 illus. in color. $b online resource.
336 $a text $b txt $2 rdacontent
337 $a computer $b c $2 rdamedia
338 $a online resource $b cr $2 rdacarrier
347 $a text file $b PDF $2 rda
490 1 $a Advances in Experimental Medicine and Biology, $x 2214-8019 ; $v 1305
505 0 $a Section I. Re-thinking depression from a network perspective -- Chapter 1. Phenotype network and brain structural covariance network of major depression -- Chapter 2. Task MRI-based functional brain network of major depression -- Chapter 3. White matter-based structural brain network of major depression -- Chapter 4. The application of a machine learning-based brain MRI approach in major depression -- Chapter 5. Resting state functional MRI in major depression -- Chapter 6. Development of neuroimaging–based biomarkers in depressive disorder -- Section II. Current diagnostic and neurobiological issues -- Chapter 7. Challenges and strategies for current classifications of depressive disorders: proposal for future diagnostic standards -- Chapter 8. Epigenetics: a missing link between early life stress and depression -- Chapter 9. Glia- neuron communications and gut-brain axis in depression -- Chapter 10. Apoptosis and proliferation markers in major depression -- Chapter 11. A load to find clinically useful biomarkers for depression -- Chapter 12. Pharmacogenomic tests for diagnosis and treatment prediction in depression -- Section III. Current specific treatments for depression -- Chapter 13. Biofeedback and neurofeedback for depression: a critical review -- Chapter 14. Cognitive behavioral therapy and mindfulness based cognitive therapy for depressive disorders -- Chapter 15. Acceptance Commitment Therapy (ACT) for major depressive disorder -- Chapter 16. Neurostimulation therapies in depressive disorders -- Chapter 17. Ketamine in major depression : New rapid antidepressant -- Chapter 18. Psychodynamic therapy in depressive disorders -- Chapter 19. Well-being therapy in depressive disorders -- Chapter 20. Complementary and alternative medicine in the treatments of depressive disorders -- Chapter 21. Current psychopharmacology algorithm for major depressive disorder -- Section IV. Promising future treatments for depression -- Chapter 22. Novel psychopharmacology for depressive disorders -- Chapter 23. Cannabinoid agents for depressive disorders -- Chapter 24. Virtual Reality for the treatment of depressive disorders -- Chapter 25. Epigenetic Therapy in depressive disorders -- Chapter 26. Induced pluripotent stem (iPS) cells technology: potential therapeutic targets for depression -- Chapter 27. Vaccination and immunotherapy for major depression -- Chapter 28. Psychedelic Medicines in major depression: progress and future challenges -- Chapter 29. Precision Psychiatry: Biomarker guided Tailored Therapy for Effective Treatment and Prevention in major depression. .
520 $a This book reviews all aspects of major depressive disorder (MDD), casting light on its neurobiological underpinnings and describing the most recent advances in management. The book is divided into four sections, the first of which discusses MDD from a network science perspective, highlighting the alterations in functional and structural connectivity and presenting insights achieved through resting state functional MRI and the development of neuroimaging-based biomarkers. The second section examines important diagnostic and neurobiological issues, while the third considers the currently available specific treatments for MDD, including biofeedback, neurofeedback, cognitive behavioral therapy, acceptance and commitment therapy, neuromodulation therapy, psychodynamic therapy, and complementary and alternative medicine. A concluding section is devoted to promising emerging treatments, from novel psychopharmacological therapies through to virtual reality treatment, immunotherapy, biomarker-guided tailored therapy, and more. Written by leading experts from across the world, the book will be an excellent source of information for both researchers and practitioners.
650 0 $a Psychopharmacology. $3 644799
650 0 $a Neurobiology. $3 573189
650 0 $a Neurosciences. $3 593561
700 1 $a Kim, Yong-Ku. $e editor. $4 edt $4 http://id.loc.gov/vocabulary/relators/edt $3 1284669
710 2 $a SpringerLink (Online service) $3 593884
773 0 $t Springer Nature eBook
776 0 8 $i Printed edition: $z 9789813360433
776 0 8 $i Printed edition: $z 9789813360457
776 0 8 $i Printed edition: $z 9789813360464
830 0 $a Advances in Experimental Medicine and Biology, $x 0065-2598 ; $v 889 $3 1253792
856 4 0 $u https://doi.org/10.1007/978-981-33-6044-0
912 $a ZDB-2-SBL
912 $a ZDB-2-SXB
950 $a Biomedical and Life Sciences (SpringerNature-11642)
950 $a Biomedical and Life Sciences (R0) (SpringerNature-43708)